Last update 08 May 2025

BL0175

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
Target-
Action-
Mechanism-
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [1]
Active Indication
HR positive solid tumorsEndometrial CarcinomaHRD-positive Ovarian Cancer+ [2]
Inactive Indication-
Originator Organization
Shanghai bestlink Biotechnology Co., Ltd
Active Organization
Shanghai bestlink Biotechnology Co., Ltd
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with BL0175
CTR20250322
/ Not yet recruitingPhase 1
评价 BL0175 注射液在绝经后激素受体阳性的局部晚期或转移性实体瘤受试者中的安全性、耐受性、药代动力学及初步疗效特征的国际多中心、开放性 I 期临床试验
[Translation] An international, multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy characteristics of BL0175 injection in postmenopausal subjects with hormone receptor-positive locally advanced or metastatic solid tumors
NCT06738966
/ Not yet recruitingPhase 1
An International, Multi-Center, Open-label Phase I Study to Evaluate the Tolerance, Pharmacokinetics, and Anti-Tumor Effects of BL0175 Injection in Postmenopausal Female Adults with HR-positive, Locally Advanced or Metastatic Cancer
100 Clinical Results associated with BL0175
Login to view more data
100 Translational Medicine associated with BL0175
Login to view more data
100 Patents (Medical) associated with BL0175
Login to view more data
100 Deals associated with BL0175
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HR positive solid tumorsPhase 1
China
Shanghai bestlink Biotechnology Co., Ltd
24 Jan 2025
HR positive solid tumorsPhase 1
Australia
Shanghai bestlink Biotechnology Co., Ltd
24 Jan 2025
Endometrial CarcinomaPhase 1
Australia
Shanghai bestlink Biotechnology Co., Ltd
20 Jan 2025
HRD-positive Ovarian CancerPhase 1
Australia
Shanghai bestlink Biotechnology Co., Ltd
20 Jan 2025
Locally advanced breast cancerPhase 1
Australia
Shanghai bestlink Biotechnology Co., Ltd
20 Jan 2025
Hormone receptor positive breast cancerIND Approval
China
Shanghai bestlink Biotechnology Co., Ltd
20 Jan 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free